echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > On the 29th World Mental Health Day, talk about the market space for antidepressants in China

    On the 29th World Mental Health Day, talk about the market space for antidepressants in China

    • Last Update: 2020-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 10, 2020, the 29th World Mental Health Day, it is worth paying more attention to one's own mental health on this special day.
    china's mental health survey results show that about 16.57 percent of the population in China suffer from a variety of mental and psychological problems.
    , mental illness mainly includes depression, bipolar disorder, schizophrenia and so on.
    , depression is a common mental disorder and one of the main causes of mental disorders worldwide.
    the World Health Organization, there are more than 350 million people with depression worldwide, including China, one of the countries with a greater burden of depression.
    According to a 2019 article published in The Lancet Psychiatry, "The lifetime prevalence of depression in China is 6.9 percent", it can be estimated that there are currently more than 95 million people with depression in China, and the number is growing.
    background, it is particularly important to call on human beings to strengthen the prevention and treatment of psychological problems, including depression.
    modern medical practice has proved that mental illness can be prevented and treated systematically, and most patients can return to society.
    at present, however, research and treatment of mental illness is very limited, both at home and abroad, and drugs can temporarily alleviate a series of symptoms of mental illness, such as sleep disorders, sensitivity and doubt.
    , the main treatments for depression include medication and psychotherapy.
    drug treatment mainly relies on antidepressants.
    studies have suggested that depression can cause hormone level disorders in patients, leading to confusion of chemicals in the brain, which exacerbates depression and therefore needs to be regulated with some medications.
    according to the Basic 2015 Edition of the Chinese Guidelines for the Prevention and Control of Antidepressant Disorders, class A recommended antidepressants include fluoxetine, paroxetine, fluoxetine, serolin, and citopran.
    there are more than 30 kinds of antidepressants in the domestic market, and the antidepressants approved for sale in China include hydrobromobromohidrene, minaplun hydrochloric acid, a gomelatin and so on.
    , minaplund hydrochloric acid has been included in China's list of basic drugs and medical insurance directory.
    is recommended as a first-line treatment for people with sleep-deprived depression and is included in the 2019 National Health Insurance Directory.
    years, the domestic antidepressant market size shows a growing trend.
    , the overall market for psychotic drugs in China reached 33.27 billion yuan in 2018, of which antidepressants accounted for 24.43 percent to 8.1 billion yuan.
    with the promotion of the "Healthy China" strategy and the change of society's understanding of depression and the concept of medical treatment, the industry believes that domestic demand for antidepressants is expected to grow and the market size will continue to expand.
    , it is worth noting that among the antidepressants used in chinese hospitals, imported drugs account for nearly 45%, and domestic drugs account for only about 10%.
    with the rising prevalence of depression and the deepening of people's understanding of depression, the domestic antidepressant market is expected to continue to grow in size, domestic antidepressants may have some room for growth.
    in recent years, domestic pharmaceutical companies, including Zhengda Tianqing, Haizheng Pharmaceuticals, Howson Pharmaceuticals and Yangzijiang and other pharmaceutical companies, have declared the listing of schizophrenia generic drugs, plus code layout of the field of mental nerves.
    2020 alone, a number of pharmaceutical companies have reported new progress in drug declarations.
    For example, Jingxin Pharmaceuticals announced that JX11502MA capsules, an innovative drug it intends to use to treat adult schizophrenia, have been approved for clinical trials, and Yangzijiang Pharmaceuticals has announced the acceptance of a market application for a generic drug called Lulacetone tablets for the treatment of adult schizophrenia under Nanjing Hailing Pharmaceuticals.
    statistics, as of August 11, the domestic neurological drugs have a class 1 new drugs and 41 generic drug market applications in the review and approval.
    Among them, in addition to focusing on the spirit, anesthesiology drugs, People's Fu Pharmaceuticals, Enhua Pharmaceuticals, Haizheng Pharmaceuticals, Zhengda Tianqing, Howson Pharmaceuticals and other pharmaceutical companies that were not involved in this field also began to lay out.
    with the launch of more drugs, it will bring good news to millions of people with mental illness in our country.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.